Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified

Explore clinical trials studying Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified. Study availability and eligibility vary by location and protocol.

4 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified trial results

Not Yet Recruiting

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

NCT07691450

Conditions: Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +36 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

NCT04074746

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT01590732

Conditions: Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +23 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions: Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations: City of Hope Medical Center Duarte, California, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

University of Nebraska Medical Center Omaha, Nebraska, United States

View Trial Details

Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified

Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified trial results

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Related conditions